Table 2.

List of clinical trials reporting the use of donor NK cells to fight relapse in patients with hematological malignancies

References	Source of NK cells	Expansion	Disease	Outcome
Passweg et al. [43]	Purified haploidentical NK cells	No	AML	Feasible, tolerated and no toxicity
Koehl et al. [44]	Donor purified PB NK cells	Yes, with IL-2	AL	Feasible, tolerated and no toxicity
Miller et al. [45]	Haploidentical PB NK cells	No	Hodgkin lymphoma, AML	Feasible, tolerated and no toxicity remission in 5/19 patients
Rubnitz et al. [46]	Haploidentical PB NK cells	No	AML	Safe, well tolerated and feasible All patients remained in remission
Bachanova et al. [47]	Haploidentical CD3-PB cells	No	Non-Hodgkin lymphoma	Safe and feasible Clinical response in 4/6 patients
Curti et al. [48]	Purified PB NK cells	No	AML	Safe and feasible Complete remission in 6/13 patients
Stern et al. [49]	Donor PB NK cells	No	Leukemia	Safe and feasible
Bachanova et al. [50]	Donor PB NK cells	No	AML	Safe and feasible

AL Acute leukemia, AML acute myeloid leukemia, aAPC artificial antigen presenting cells, CLL chronic lymphoblastic lymphoma, MM multiple myeloma, PB peripheral blood